Rallybio Corporation

RLYB

$16.88

-0.38%

2026-09-03 16:00:00 EDT-$0.07

Healthcare

Biotechnology

NASDAQ

Active Trading

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon ...

Historical Employee Count of RLYB

Current

Change

-44.00%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	14	10-K	Mar 16, 2026	View
Dec 31, 2024	25	10-K	Mar 13, 2025	View
Dec 31, 2023	43	10-K	Mar 12, 2024	View
Dec 31, 2022	41	10-K	Mar 6, 2023	View
Dec 31, 2021	35	10-K	Mar 15, 2022	View

Supply Chain of RLYB

Upstream / Downstream / Proxies

Upstream

Affibody ABSwedish Orphan Biovitrum AB (Sobi)STO:SOBIAbCellera Biologics Inc.NASDAQ:ABCL Recursion Pharmaceuticals (via Exscientia legacy)NASDAQ:RXRX Johnson & Johnson Innovation — JJDCNYSE:JNJUnnamed CDMO Partner(s)Unnamed CRO Partner(s)

Downstream

Johnson & Johnson (via Momenta Pharmaceuticals subsidiary)NYSE:JNJAvenzo TherapeuticsUnconfirmedRecursion PharmaceuticalsNASDAQ:RXRX

Proxies

Apellis Pharmaceuticals Inc.NASDAQ:APLS Alexion Pharmaceuticals (AstraZeneca Rare Disease)NASDAQ:AZN Recursion Pharmaceuticals Inc.NASDAQ:RXRXCandid Therapeutics Inc.Unconfirmed

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer